Literature DB >> 9062142

Indispensability of pelvic and paraaortic lymphadenectomy in endometrial cancers.

Y Yokoyama1, H Maruyama, S Sato, Y Saito.   

Abstract

The purposes of this study were to analyze the relationship between retroperitoneal lymph node (RLN) metastasis and clinical and pathologic risk factors in endometrial cancers, and to clarify the correlation between RLN metastasis and survival of patients with the disease. This analysis included 63 patients with endometrial cancer who underwent simultaneous pelvic lymph node (PLN) and paraaortic lymph node (PAN) dissection between April 1988 and December 1995. Patients with stage Ia grade 1 and stage IV disease were excluded from this analysis. Both PLN and PAN metastases were found in 10.0% (4/40) of patients with stage I (FIGO, 1988) disease. Of 14 cases with PLN metastases, 8 (57.1%) had PAN metastases simultaneously, whereas 4 (8.2%) of 49 cases without PLN metastases had PAN metastases. There was no significant relationship between the sites or numbers of positive PLN and PAN metastases. Multivariate analysis revealed that poor grade and deep myometrial invasion had an independent relationship with PAN metastases, whereas vascular space invasion and cervical invasion were independently associated with PLN metastases. When divided into the groups of stage I-II and stage III, the prognosis of patients with RLN metastases was significantly poorer than that of patients without RLN metastases in each stage. Furthermore, survival of patients with PAN metastases was significantly worse compared with that of patients with only PLN metastases (44.4 and 80.0%, respectively, P < 0.05). These results reveal that PLN and PAN metastases occur frequently even in early-stage endometrial cancer, and that RLN metastases, especially PAN metastases, have a serious impact on patient survival. In conclusion, systemically simultaneous pelvic and paraaortic lymphadenectomy is essential for all the patients with endometrial cancer except those with stage Ia grade 1 and stage IV to provide prognostic information and select suitable postoperative treatment as well as to perform accurate FIGO staging, provided the condition of the patient permits.

Entities:  

Mesh:

Year:  1997        PMID: 9062142     DOI: 10.1006/gyno.1996.4573

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  14 in total

1.  Major clinical research advances in gynecologic cancer in 2010.

Authors:  Dong Hoon Suh; Jae Weon Kim; Kidong Kim; Soon-Beom Kang
Journal:  J Gynecol Oncol       Date:  2010-12-31       Impact factor: 4.401

2.  Lymphadenectomy should be performed up to the renal vein in patients with intermediate-high risk endometrial cancer.

Authors:  Ismail Alay; Taner Turan; Isin Ureyen; Alper Karalok; Tolga Tasci; Ahmet Ozfuttu; M Faruk Kose; Gokhan Tulunay
Journal:  Pathol Oncol Res       Date:  2015-01-07       Impact factor: 3.201

3.  Selected immuno-histochemical markers in curettage specimens and their correlation with final pathologic findings in endometrial cancer patients.

Authors:  Basil R Obeidat; Ismail I Matalka; Alia A Mohtaseb; Nabih S Al-Kaisi
Journal:  Pathol Oncol Res       Date:  2012-10-10       Impact factor: 3.201

4.  The risk and pattern of pelvic and para aortic lymph nodal metastasis in patients with intermediate and high risk endometrial cancer.

Authors:  Praveen S Rathod; P N Shakuntala; V R Pallavi; Rajashekar Kundaragi; B Shankaranand; C R Vijay; K Uma Devi; Uttam D Bafna
Journal:  Indian J Surg Oncol       Date:  2014-03-28

5.  A study of pelvic and para-aortic lymph node involvement in surgically staged endometrioid carcinoma of endometrium.

Authors:  Rekha B Raghavendrachar; Julian Crasta; Premalatha T Siddartha; Elizabeth M Vallikad
Journal:  J Obstet Gynaecol India       Date:  2013-04-11

6.  Systemic lymphadenectomy cannot be recommended for low-risk corpus cancer.

Authors:  Takao Hidaka; Akitoshi Nakashima; Tomoko Shima; Toru Hasegawa; Shigeru Saito
Journal:  Obstet Gynecol Int       Date:  2010-02-04

7.  Major clinical research advances in gynecologic cancer 2008.

Authors:  Kidong Kim; Seok-Cheol Choi; Sang-Young Ryu; Jae Weon Kim; Soon-Beom Kang
Journal:  J Gynecol Oncol       Date:  2008-12-29       Impact factor: 4.401

8.  Prospective assessment of lymphatic dissemination in endometrial cancer: a paradigm shift in surgical staging.

Authors:  Andrea Mariani; Sean C Dowdy; William A Cliby; Bobbie S Gostout; Monica B Jones; Timothy O Wilson; Karl C Podratz
Journal:  Gynecol Oncol       Date:  2008-03-04       Impact factor: 5.482

9.  Survival analysis of pelvic lymphadenectomy alone versus combined pelvic and para-aortic lymphadenectomy in patients exhibiting endometrioid type endometrial cancer.

Authors:  Tayfun Toptas; Tayup Simsek
Journal:  Oncol Lett       Date:  2014-10-31       Impact factor: 2.967

10.  Lymphadenectomy and adjuvant therapy in endometrial carcinoma: role of adjuvant chemotherapy.

Authors:  I Otsuka; T Kubota; T Aso
Journal:  Br J Cancer       Date:  2002-08-12       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.